Ï㽶ÊÓƵ

Satoshi Minoshima
No Rating Available
(Learn About Our Rating System)

Satoshi Minoshima, MD, PhD

Languages spoken: English, Japanese

  • Satoshi Minoshima, M.D., Ph.D. is Professor and Chair in the Department of Radiology and Imaging Sciences at the Ï㽶ÊÓƵ of Utah. Dr. Minoshima is a radiologist specialized in Nuclear Medicine and Molecular Imaging. His scientific contributions in the field of Neuroscience include the discovery of very early sign of Alzheimer's disease in the posterior cingulate cortex and worldwide dissemination of diagnostic statistical mapping technology. He has published over 170 peer reviewed articles and numerous book chapters, review articles, proceedings, and abstracts, and given over 300 presentations. He served as the President of the Brain Imaging Council for the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and currently serves as the SNMMI Chair of the Scientific Program Committee, SNMMI Vice President Elect, as well as the Chair of the Molecular Imaging Committee for the Radiological Society of North America (RSNA). He also works with the United Nations / International Atomic Energy Agency to advance the peaceful use of nuclear technology in medicine. Dr. Minoshima has received multiple awards including Tetalman Memorial Award in 1996 and Kuhl-Lassen Award in 2006 from the SNMMI; Gold Medal from the American Roentgen Ray Society (ARRS) in 2013; Clinical Teaching Award of the Year in 2014; the Ï㽶ÊÓƵ of Washington Presidential Entrepreneur Faculty Fellow Award in 2014; and the SNMMI Presidential Distinguished Service Award in 2016.

    Specialties

    Board Certification

    American Board of Nuclear Medicine
    Educational Commission for Foreign Medical Graduates
    Federal Licensing Examination
    Japanese Board of Radiology (Diagnostic Radiology)
    Japanese Board of Radiology (Nuclear Medicine)
    Japanese Board of Radiology (Radiation Oncology)

  • Satoshi Minoshima, M.D., Ph.D. is Professor and Chair in the Department of Radiology and Imaging Sciences at the Ï㽶ÊÓƵ of Utah. Dr. Minoshima is a radiologist specialized in Nuclear Medicine and Molecular Imaging. His scientific contributions in the field of Neuroscience include the discovery of very early sign of Alzheimer's disease in the posterior cingulate cortex and worldwide dissemination of diagnostic statistical mapping technology. He has published over 170 peer reviewed articles and numerous book chapters, review articles, proceedings, and abstracts, and given over 300 presentations. He served as the President of the Brain Imaging Council for the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and currently serves as the SNMMI Chair of the Scientific Program Committee, SNMMI Vice President Elect, as well as the Chair of the Molecular Imaging Committee for the Radiological Society of North America (RSNA). He also works with the United Nations / International Atomic Energy Agency to advance the peaceful use of nuclear technology in medicine. Dr. Minoshima has received multiple awards including Tetalman Memorial Award in 1996 and Kuhl-Lassen Award in 2006 from the SNMMI; Gold Medal from the American Roentgen Ray Society (ARRS) in 2013; Clinical Teaching Award of the Year in 2014; the Ï㽶ÊÓƵ of Washington Presidential Entrepreneur Faculty Fellow Award in 2014; and the SNMMI Presidential Distinguished Service Award in 2016.

    Board Certification and Academic Information

    Academic Departments Radiology & Imaging Sciences -Primary
    Board Certification
    American Board of Nuclear Medicine
    Educational Commission for Foreign Medical Graduates
    Federal Licensing Examination
    Japanese Board of Radiology (Diagnostic Radiology)
    Japanese Board of Radiology (Nuclear Medicine)
    Japanese Board of Radiology (Radiation Oncology)

    Education history

    Postdoctoral Fellowship Nuclear Medicine - Ï㽶ÊÓƵ of Michigan Postdoctoral Fellow
    Doctoral Training Radiological Science - Chiba Ï㽶ÊÓƵ School of Medicine Ph.D.
    Residency Radiology - Chiba Ï㽶ÊÓƵ Hospital Resident
    Professional Medical Medicine - Chiba Ï㽶ÊÓƵ School of Medicine M.D.

    Selected Publications

    Journal Article

    1. Meabon JS, Huber BR, Cross DJ, Richards TL, Minoshima S, Pagulayan KF, Li G, Meeker KD, Kraemer BC, Petrie EC, Raskind MA, Peskind ER, Cook DG (2016). Repetitive blast exposure in mice and combat veterans causes persistent cerebellar dysfunction. Sci Transl Med, 8(321), 321ra6. ()
    2. Mitsumori LM, McDonald ES, Wilson GJ, Neligan PC, Minoshima S, Maki JH (2015). MR lymphangiography: How i do it. J Magn Reson Imaging, 42(6), 1465-77. ()
    3. Matesan MC, Cross DJ, Lewis DH, Minoshima S (2015). Differential alterations of dopamine transporter in the striatum and midbrain in patients with parkinsonian syndrome. Clin Nucl Med, 40(3), 191-4. ()
    4. Sham JG, Kievit FM, Grierson JR, Chiarelli PA, Miyaoka RS, Zhang M, Yeung RS, Minoshima S, Park JO (2014). Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma. J Nucl Med, 55(12), 2032-7. ()
    5. Drzezga A, Barthel H, Minoshima S, Sabri O (2014). Potential Clinical Applications of PET/MR Imaging in Neurodegenerative Diseases. J Nucl Med, 55(Supplement 2), 47S-55S. ()
    6. Sham JG, Kievit FM, Grierson JR, Miyaoka RS, Yeh MM, Zhang M, Yeung RS, Minoshima S, Park JO (2014). Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma. J Nucl Med, 55(5), 799-804. ()
    7. Cross DJ, Anzai Y, Petrie EC, Martin N, Richards TL, Maravilla KR, Peskind ER, Minoshima S (2013). Loss of olfactory tract integrity affects cortical metabolism in the brain and olfactory regions in aging and mild cognitive impairment. J Nucl Med, 54(8), 1278-84. ()
    8. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Hedrick S, Pappas V, Carrillo MC, Hartley DM (2013). Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging. Alzheimers Dement, 9(4), e106-9. ()
    9. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Hedrick S, Pappas V, Carrillo MC, Hartley DM (2013). Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. J Nucl Med, 54(7), 1011-3. ()
    10. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, Hedrick S, Pappas V, Thies WH (2013). Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med, 54(3), 476-90. ()
    11. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, Hedrick S, Pappas V, Thies WH (2013). Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement, 9(1), e-1-16. ()
    12. Casey KL, Geisser M, Lorenz J, Morrow TJ, Paulson P, Minoshima S (2012). Psychophysical and cerebral responses to heat stimulation in patients with central pain, painless central sensory loss, and in healthy persons. Pain, 153(2), 331-41. ()
    13. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B (2012). Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol, 69(1), 29-38. ()
    14. Bohnen NI, Koeppe RA, Minoshima S, Giordani B, Albin RL, Frey KA, Kuhl DE (2011). Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med, 52(6), 848-55. ()
    15. Flexman JA, Cross DJ, Tran LN, Sasaki T, Kim Y, Minoshima S (2011). Quantitative analysis of neural stem cell migration and tracer clearance in the rat brain by MRI. Mol Imaging Biol, 13(1), 104-11. ()
    16. Peskind ER, Petrie EC, Cross DJ, Pagulayan K, McCraw K, Hoff D, Hart K, Yu CE, Raskind MA, Cook DG, Minoshima S (2011). Cerebrocerebellar hypometabolism associated with repetitive blast exposure mild traumatic brain injury in 12 Iraq war Veterans with persistent post-concussive symptoms. Neuroimage, 54 Suppl 1, S76-82. ()
    17. Petrie EC, Cross DJ, Galasko D, Schellenberg GD, Raskind MA, Peskind ER, Minoshima S (2009). Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Arch Neurol, 66(5), 632-7. ()
    18. Dighe M, Bae U, Richardson ML, Dubinsky TJ, Minoshima S, Kim Y (2008). Differential diagnosis of thyroid nodules with US elastography using carotid artery pulsation. Radiology, 248(2), 662-9. ()
    19. Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, Reiman EM, Holthoff V, Kalbe E, Sorbi S, Diehl-Schmid J, Perneczky R, Clerici F, Caselli R, Beuthien-Baumann B, Kurz A, Minoshima S, de Leon MJ (2008). Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med, 49(3), 390-8. ()
    20. Cross DJ, Flexman JA, Anzai Y, Maravilla KR, Minoshima S (2008). Age-related decrease in axonal transport measured by MR imaging in vivo. Neuroimage, 39(3), 915-26. ()
    21. Cross DJ, Flexman JA, Anzai Y, Sasaki T, Treuting PM, Maravilla KR, Minoshima S (2007). In vivo manganese MR imaging of calcium influx in spontaneous rat pituitary adenoma. AJNR Am J Neuroradiol, 28(10), 1865-71. ()
    22. Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, DeCarli CS, Turner RS, Koeppe RA, Higdon R, Minoshima S (2007). FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain, 130(Pt 10), 2616-35. ()
    23. Mosconi L, Tsui WH, Pupi A, De Santi S, Drzezga A, Minoshima S, de Leon MJ (2007). (18)F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease. J Nucl Med, 48(7), 1129-34. ()
    24. Cross DJ, Flexman JA, Anzai Y, Morrow TJ, Maravilla KR, Minoshima S (2006). In vivo imaging of functional disruption, recovery and alteration in rat olfactory circuitry after lesion. Neuroimage, 32(3), 1265-72. ()
    25. Flexman JA, Minoshima S, Kim Y, Miyoshi S, Lewellen BL, Cross DJ (2006). A viral envelope as a vehicle for tracer, drug, and gene delivery. IEEE Eng Med Biol Mag, 25(4), 70-5. ()
    26. Kuhl DE, Koeppe RA, Snyder SE, Minoshima S, Frey KA, Kilbourn MR (2006). In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses. Ann Neurol, 59(1), 13-20. ()
    27. Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, Minoshima S, Schwaiger M, Kurz A (2005). Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med, 46(10), 1625-32. ()
    28. Drzezga A, Riemenschneider M, Strassner B, Grimmer T, Peller M, Knoll A, Wagenpfeil S, Minoshima S, Schwaiger M, Kurz A (2005). Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology, 64(1), 102-7. ()
    29. Cross DJ, Minoshima S, Anzai Y, Flexman JA, Keogh BP, Kim Y, Maravilla KR (2004). Statistical mapping of functional olfactory connections of the rat brain in vivo. Neuroimage, 23(4), 1326-35. ()
    30. Casey KL, Lorenz J, Minoshima S (2003). Insights into the pathophysiology of neuropathic pain through functional brain imaging. Exp Neurol, 184 Suppl 1, S80-8. ()
    31. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, Schwaiger M, Kurz A (2003). Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging, 30(8), 1104-13. ()
    32. Lorenz J, Cross DJ, Minoshima S, Morrow TJ, Paulson PE, Casey KL (2002). A unique representation of heat allodynia in the human brain. Neuron, 35(2), 383-93. ()
    33. Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE (2001). Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol, 50(3), 358-65. ()
    34. Casey KL, Morrow TJ, Lorenz J, Minoshima S (2001). Temporal and spatial dynamics of human forebrain activity during heat pain: analysis by positron emission tomography. J Neurophysiol, 85(2), 951-9. ()
    35. Ladabaum U, Minoshima S, Hasler WL, Cross D, Chey WD, Owyang C (2001). Gastric distention correlates with activation of multiple cortical and subcortical regions. Gastroenterology, 120(2), 369-76. ()
    36. Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA (2000). Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol, 48(3), 391-5. ()
    37. Casey KL, Svensson P, Morrow TJ, Raz J, Jone C, Minoshima S (2000). Selective opiate modulation of nociceptive processing in the human brain. J Neurophysiol, 84(1), 525-33. ()
    38. Anzai Y, Minoshima S, Wolf GT, Wahl RL (1999). Head and neck cancer: detection of recurrence with three-dimensional principal components analysis at dynamic FDG PET. Radiology, 212(1), 285-90. ()
    39. Drzezga A, Arnold S, Minoshima S, Noachtar S, Szecsi J, Winkler P, Romer W, Tatsch K, Weber W, Bartenstein P (1999). 18F-FDG PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis. J Nucl Med, 40(5), 737-46. ()
    40. Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, Frey KA, Kilbourn MR (1999). In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology, 52(4), 691-9. ()
    41. Bohnen NI, Minoshima S, Giordani B, Frey KA, Kuhl DE (1999). Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurology, 52(3), 541-6. ()
    42. Minoshima S, Cross DJ, Foster NL, Henry TR, Kuhl DE (1999). Discordance between traditional pathologic and energy metabolic changes in very early Alzheimer's disease. Pathophysiological implications. Ann N Y Acad Sci, 893, 350-2. ()
    43. Bartenstein P, Minoshima S, Hirsch C, Buch K, Willoch F, Mosch D, Schad D, Schwaiger M, Kurz A (1997). Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by SPECT. J Nucl Med, 38(7), 1095-101. ()
    44. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE (1997). Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol, 42(1), 85-94. ()
    45. Vander Borght T, Minoshima S, Giordani B, Foster NL, Frey KA, Berent S, Albin RL, Koeppe RA, Kuhl DE (1997). Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. J Nucl Med, 38(5), 797-802. ()
    46. Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, Wieland DM, Koeppe RA (1996). In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol, 40(3), 399-410. ()
    47. Albin RL, Minoshima S, DAmato CJ, Frey KA, Kuhl DA, Sima AA (1996). Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology, 47(2), 462-6. ()
    48. Casey KL, Minoshima S, Morrow TJ, Koeppe RA (1996). Comparison of human cerebral activation pattern during cutaneous warmth, heat pain, and deep cold pain. J Neurophysiol, 76(1), 571-81. ()
    49. Anzai Y, Carroll WR, Quint DJ, Bradford CR, Minoshima S, Wolf GT, Wahl RL (1996). Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses. Radiology, 200(1), 135-41. ()
    50. Frey KA, Minoshima S, Koeppe RA, Kilbourn MR, Berger KL, Kuhl DE (1996). Stereotaxic summation analysis of human cerebral benzodiazepine binding maps. J Cereb Blood Flow Metab, 16(3), 409-17. ()
    51. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D (1996). Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med, 334(12), 752-8. ()
    52. Burdette JH, Minoshima S, Vander Borght T, Tran DD, Kuhl DE (1996). Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections. Radiology, 198(3), 837-43. ()
    53. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE (1995). A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med, 36(7), 1238-48. ()
    54. Smith EE, Jonides J, Koeppe RA, Awh E, Schumacher EH, Minoshima S (1995). Spatial versus Object Working Memory: PET Investigations. J Cogn Neurosci, 7(3), 337-56. ()
    55. Minoshima S, Foster NL, Kuhl DE (1994). Posterior cingulate cortex in Alzheimer's disease. Lancet, 344(8926), 895. ()
    56. Minoshima S, Koeppe RA, Frey KA, Kuhl DE (1994). Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med, 35(9), 1528-37. ()
    57. Casey KL, Minoshima S, Berger KL, Koeppe RA, Morrow TJ, Frey KA (1994). Positron emission tomographic analysis of cerebral structures activated specifically by repetitive noxious heat stimuli. J Neurophysiol, 71(2), 802-7. ()
    58. Jonides J, Smith EE, Koeppe RA, Awh E, Minoshima S, Mintun MA (1993). Spatial working memory in humans as revealed by PET. Nature, 363(6430), 623-5. ()
    59. Minoshima S, Koeppe RA, Mintun MA, Berger KL, Taylor SF, Frey KA, Kuhl DE (1993). Automated detection of the intercommissural line for stereotactic localization of functional brain images. J Nucl Med, 34(2), 322-9. ()
    60. Minoshima S, Berger KL, Lee KS, Mintun MA (1992). An automated method for rotational correction and centering of three-dimensional functional brain images. J Nucl Med, 33(8), 1579-85. ()

    Patent

    1. Thiele FO, Minoshima S (2014). Image based clinical trial assessment. U.S. Patent No. US 8805036 B2. Washington, D.C.:U.S. Patent and Trademark Office.
    2. Minoshima S (2013). Glypican-3 Targeted 89Zr-PET Imaging of HCC, 12/17/2013, patent application number 61/917,164, UW Reference: 46651.01US1.
    3. Minoshima S (2011). Intranasal delivery of axonal stabilizing agents to the brain, patent application number 61/551,796, UW Reference: 45744.01US1.
    4. Minoshima S (2008). Methods and Apparatus for determining brain cortical thickness.
    5. Minoshima S (2008). A device (method) for generating alternative of normal brain database.
    6. Blumenfeld J, Avinash G, Bridge W, Sirohey S, Minoshima S (2007). Systems, methods, and apparatus for creation of a database of images from categorical indices. U.S. Patent No. US20070081700 A1. Washington, D.C.:U.S. Patent and Trademark Office.
    7. Sirohey SA, Avinash GB, Blumenfeld J, Bridge WJ, Minoshima S (2007). Systems, methods, and apparatus for tracking progression and tracking treatment of disease from categorical indices. U.S. Patent No. US20070081701 A1. Washington, D.C.:U.S. Patent and Trademark Office.
    8. Avinash G, Bridge W, Sirohey S, Blumenfeld J, Minoshima S (2007). Systems, methods, and apparatus for diagnosis of disease from categorical indices. U.S. Patent No. US20070081699 A1. Washington, D.C.:U.S. Patent and Trademark Office.

  • News & Podcasts

    News